283 related articles for article (PubMed ID: 32822394)
1. Raman chemometric urinalysis (Rametrix) as a screen for bladder cancer.
Huttanus HM; Vu T; Guruli G; Tracey A; Carswell W; Said N; Du P; Parkinson BG; Orlando G; Robertson JL; Senger RS
PLoS One; 2020; 15(8):e0237070. PubMed ID: 32822394
[TBL] [Abstract][Full Text] [Related]
2. Spectral characteristics of urine specimens from healthy human volunteers analyzed using Raman chemometric urinalysis (Rametrix).
Senger RS; Kavuru V; Sullivan M; Gouldin A; Lundgren S; Merrifield K; Steen C; Baker E; Vu T; Agnor B; Martinez G; Coogan H; Carswell W; Karageorge L; Dev D; Du P; Sklar A; Orlando G; Pirkle J; Robertson JL
PLoS One; 2019; 14(9):e0222115. PubMed ID: 31560690
[TBL] [Abstract][Full Text] [Related]
3. Spectral characteristics of urine from patients with end-stage kidney disease analyzed using Raman Chemometric Urinalysis (Rametrix).
Senger RS; Sullivan M; Gouldin A; Lundgren S; Merrifield K; Steen C; Baker E; Vu T; Agnor B; Martinez G; Coogan H; Carswell W; Kavuru V; Karageorge L; Dev D; Du P; Sklar A; Pirkle J; Guelich S; Orlando G; Robertson JL
PLoS One; 2020; 15(1):e0227281. PubMed ID: 31923235
[TBL] [Abstract][Full Text] [Related]
4. Disease-Associated Multimolecular Signature in the Urine of Patients with Lyme Disease Detected Using Raman Spectroscopy and Chemometrics.
Senger RS; Sayed Issa A; Agnor B; Talty J; Hollis A; Robertson JL
Appl Spectrosc; 2022 Mar; 76(3):284-299. PubMed ID: 35102746
[TBL] [Abstract][Full Text] [Related]
5. Identification and validation of AIB1 and EIF5A2 for noninvasive detection of bladder cancer in urine samples.
Zhou BF; Wei JH; Chen ZH; Dong P; Lai YR; Fang Y; Jiang HM; Lu J; Zhou FJ; Xie D; Luo JH; Chen W
Oncotarget; 2016 Jul; 7(27):41703-41714. PubMed ID: 27203388
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
7. Analysis of urine Raman spectra differences from patients with diabetes mellitus and renal pathologies.
Kavuru V; Senger RS; Robertson JL; Choudhury D
PeerJ; 2023; 11():e14879. PubMed ID: 36874959
[TBL] [Abstract][Full Text] [Related]
8. Alterations in the molecular composition of COVID-19 patient urine, detected using Raman spectroscopic/computational analysis.
Robertson JL; Senger RS; Talty J; Du P; Sayed-Issa A; Avellar ML; Ngo LT; Gomez De La Espriella M; Fazili TN; Jackson-Akers JY; Guruli G; Orlando G
PLoS One; 2022; 17(7):e0270914. PubMed ID: 35849572
[TBL] [Abstract][Full Text] [Related]
9. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
[TBL] [Abstract][Full Text] [Related]
10. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.
Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC
BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739
[TBL] [Abstract][Full Text] [Related]
12. Developing urinary metabolomic signatures as early bladder cancer diagnostic markers.
Shen C; Sun Z; Chen D; Su X; Jiang J; Li G; Lin B; Yan J
OMICS; 2015 Jan; 19(1):1-11. PubMed ID: 25562196
[TBL] [Abstract][Full Text] [Related]
13. Bladder cancer risk stratification using a urinary mRNA biomarker panel - A path towards cystoscopy triaging.
Shkolyar E; Zhao Q; Mach KE; Teslovich NC; Lee TJ; Cox S; Skinner EC; Lu Y; Liao JC
Urol Oncol; 2021 Aug; 39(8):497.e9-497.e15. PubMed ID: 33766467
[TBL] [Abstract][Full Text] [Related]
14. CCL18 in a multiplex urine-based assay for the detection of bladder cancer.
Urquidi V; Kim J; Chang M; Dai Y; Rosser CJ; Goodison S
PLoS One; 2012; 7(5):e37797. PubMed ID: 22629457
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer.
Kehinde EO; Al-Mulla F; Kapila K; Anim JT
Scand J Urol Nephrol; 2011 Mar; 45(2):113-21. PubMed ID: 21091091
[TBL] [Abstract][Full Text] [Related]
16. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
[TBL] [Abstract][Full Text] [Related]
17. Urinary levels of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein as a diagnostic biomarker in patients with bladder cancer.
Nitta Y; Konishi H; Makino T; Tanaka T; Kawashima H; Iovanna JL; Nakatani T; Kiyama H
BMC Urol; 2012 Sep; 12():24. PubMed ID: 22943287
[TBL] [Abstract][Full Text] [Related]
18. HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease.
Tripathi P; Somashekar BS; Ponnusamy M; Gursky A; Dailey S; Kunju P; Lee CT; Chinnaiyan AM; Rajendiran TM; Ramamoorthy A
J Proteome Res; 2013 Jul; 12(7):3519-28. PubMed ID: 23731241
[TBL] [Abstract][Full Text] [Related]
19. Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer.
Chen X; Zhang J; Ruan W; Huang M; Wang C; Wang H; Jiang Z; Wang S; Liu Z; Liu C; Tan W; Yang J; Chen J; Chen Z; Li X; Zhang X; Xu P; Chen L; Xie R; Zhou Q; Xu S; Irwin DL; Fan JB; Huang J; Lin T
J Clin Invest; 2020 Dec; 130(12):6278-6289. PubMed ID: 32817589
[TBL] [Abstract][Full Text] [Related]
20. Bladder cancer biomarker discovery using global metabolomic profiling of urine.
Wittmann BM; Stirdivant SM; Mitchell MW; Wulff JE; McDunn JE; Li Z; Dennis-Barrie A; Neri BP; Milburn MV; Lotan Y; Wolfert RL
PLoS One; 2014; 9(12):e115870. PubMed ID: 25541698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
